Monthly PrEP pill could be made for US$3 a year, but Latin America is shut out of generic licensing
Manufacturer’s plans for equitable access to twice-yearly PrEP under fire
No HIV infections seen in groundbreaking trial of twice-yearly injectable PrEP
Children in Kenya and Uganda experiencing stock-outs of crucial HIV medicines like dolutegravir
Zimbabwe shows how to make new HIV prevention products available quickly
Injectable HIV treatment unlikely to be arriving soon in the global south
Novel drugs that turn HIV against itself might clear infected cells from the body
Cabotegravir long-acting PrEP out of reach for upper middle-income nations
Not counted: clinical trials of new HIV treatments are failing women
